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A B S T R A C T
In this review an overview of current literature on the topic of the relation between sex steroid hormones and cardio-
vascular diseases (CVDs) is presented. The influence of the mentioned hormones on the three levels has been analyzed:
their interaction with the blood vessel receptors, their modulation of the vascular function, and finally their role in the
pathogenesis of CVDs. This review is focused not only on already known facts of the protective role of estrogens and the
inceptive role of testosterone, but attempts to give examples of their opposite effects on vascular function and development
of CVDs.
Key words: estrogens, progesterone, sex steroid hormones, testosterone, androgens, hypertension, and cardiovascu-
lar diseases
Introduction
Cardiovascular diseases (CVDs), such as myocardial
infarction and cerebral insult, are the major cause of
death in the developed societies with approximately 50%
of all mortality1. There are two major groups of risk fac-
tors involved in the pathogenesis of CVDs: constitutional
(e.g. age, gender, heredity) and acquired (e.g. hyperli-
pidemia, hypertension, smoking, diabetes). It should be
mentioned that obesity by itself plays its role as well as
an independent risk factor for coronary artery disease1.
Epidemiological studies have shown the same morbidity
and mortality of CVDs between men and postmeno-
pausal women of the same age, but also great differences
in these two parameters between men and premeno-
pausal woman of the same age1. These differences could
be attributed to the specific effects of sex steroid hor-
mones on vascular function. Estrogens and progesterone
are commonly considered as protectors against CVDs2,
while the role of androgens and testosterone in ethio-
pathogenesis of CVDs has not been fully established yet,
although some studies suggest that androgens have pro-
tective role in the development of cardiovascular disea-
ses3.
Molecular Actions of Sex Hormones on
the Blood Vessel Receptors
Receptors for estrogens, progesterone, and testoster-
one are expressed in varying numbers in both the endo-
thelium and vascular smooth muscle cells (VSMCs) of
multiple vascular systems. There are two subtypes of
estrogens receptor (ER) in human body; ER-a and ER-â.
The protective effects of estrogens in a response to a vas-
cular injury are mediated by ER-a, although the ER-â is
the receptor which is more widely expressed in human
VSMCs, especially in female gender. There are two types
of progesterone receptor as well; A and B. Progesterone
receptor type B mediates the regulation of gene tran-
scription and VSM cell proliferation2.
Two general signaling pathways are activated by sex
hormones. The common one is genomic pathway, which
involves binding of a sex hormone to an intracellular re-
ceptor. After binding between a sex hormone and its spe-
cific receptor, two hormone/receptor complexes are bind
together and undergo phosphorylation, which enables
them to act as a transcription factor. This means that the
complex binds to specific sites on the regulatory region of
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a target gene. The final result is an increase or decrease
in the synthesis of the protein coded by that gene3.
The second, much faster pathway, is non-genomic sex
hormone signal transduction pathway, where the binding
between sex hormones and the receptors occurs on the
surface of the cells, and could directly and indirectly af-
fects membrane ion channels, induce the elevation of
intracellular calcium as a second messenger, or is involv-
ing the interaction of sex steroids with the other signal
transduction pathways such as the tyrosine kinase and
mitogen – activating protein (MAP) kinase pathways3. Li
et al.4 reported that the ER co-activator steroid receptor
co-activator 3 (SRC3) is also a co-activator for the major
VSM transcription factor myocardin, which is required
for VSM differentiation to the non-proliferative, contrac-
tile state. The SRC3-myocardin interaction identifies a
site of convergence for nuclear hormone receptor-medi-
ated and VSM-specific gene regulation and suggests a
possible mechanism for the vascular protective effects of
estrogens on vascular injury. Nakamura et al5 examined
the relative levels of prostaglandin PR isoform (PR-A
and PR-B) expression in VSM. PR-B is cell-specific and
transcriptional more active than PR-A. The PR-A iso-
form has been demonstrated to repress the transcriptio-
nal activities of other steroid hormone receptors. The rel-
ative level of PR-A expression was more abundant in
VSMCs of the female aorta than in those of the male
aorta, but the relative level of PR-B expression was not
different between male and female aortas. This suggests
that PR-A isoform may have protective role against de-
velopment of CVDs in women.
Significant Changes in Vascular Function
Due to Sex Hormones
A fine balance between vasoconstrictor signals, such
as catecholamines, endothelium 1 (ET-1), tromboxane A2
(TXA2), prostaglandin F2a, (PGF2a), and angiotensin II;
and vasodilator mediators, primarily NO, endothelium-
-derived hyperpolarizing factors (EDHF; known as me-
tabolite of arachidonic acid – epoxyeicosatrienoic acids,
EET), and PGI2, determines vascular tone and subse-
quently blood flow to organs and tissue perfusion. Some
prostaglandins, such as PGE2, can function as both,
vasoconstrictor and vasodilator, depending on the type of
receptor they bound at, i.e. EP1 or EP3 prostanoid recep-
tors2. Nitric oxide is the principal mediator of endothe-
lium-dependent vasodilatation. Signals such as ATP, bra-
dykinin, histamine, adenosine, acetylcholine, cytokines,
vessel wall distension and shear stress (caused by blood
flow and increased by turbulent flow) stimulate the pro-
duction of nitric oxide6. EDHF are factors that activate
Ca2+-activated K+ channels (BKCa) and cause hyperpo-
larization and relaxation of the smooth muscle independ-
ently of NO-cGMP and the PGI2-cAMP pathways.
Endothelium-dependent relaxation is greater in fe-
males compared to males, which may be related to differ-
ences in the endothelium-dependent hyperpolarization
of VSM in response to EDHF. In estrogen-deficient states
relaxation in response to EDHF is attenuated. Interest-
ingly, testosterone may also release endothelium-derived
substances that cause hyperpolarization of the cells par-
tially by a mechanism that involves voltage-dependent
and BKCa channels, and partially, by endothelium-inde-
pendent way that may involve ATP-sensitive K+ chan-
nels2. One could speculate that the sensitivity to EDHF
could be changed, or that some other pathways could be
activated when estrogen levels are decreased, as in post-
-menopausal period of woman’s life, leading to impaired
vascular function and increased risks for CVDs.
Changes in vascular function are crucial pathogenic
factors in many complex multifactor diseases, such as hy-
percholesterolemia, ischemia-reperfusion injury, diabe-
tes and hypertension. In these conditions, reactive oxy-
gen species (ROS) are known to play an important role as
well7–10. However, the exact mechanism by which oxida-
tive stress exerts its effects is not yet fully elucidated.
There probably exists a role for oxidant signaling in
physiological (sensing of pO2 changes) and pathophysio-
logical (vascular proliferate processes, attenuation of va-
sodilator mechanisms) responses10. Observations suggest
that super-oxide anions can affect physiological vascular
reactivity or impair blood flow auto-regulation11–13.
Taking into account the differences in cardiovascular
morbidity between men and women, as well as the fact
that vascular dysfunction is essential in the pathogenesis
of diseases like diabetes and hypertension14; it is plausi-
ble that steroid sex hormones may have a direct influ-
ence on vascular reactivity and function. Gender dif-
ferences in endothelium, meaning dependent vascular
responses to various vasodilator stimuli are widely dem-
onstrated in animal models and in human studies. For
example, experiments on aortic rings confirmed that
there were sex-specific differences in aortic sensitivity to
vasoactive stimuli in consomic rat strains on high-salt
diet15. In addition, a study by Subakir et al showed that
arteries from women exhibit greater flow – mediated di-
lation compared to man in response to reactive hyper-
aemia3. Majmudar et al found that the vasoconstrictive
response to a nitric oxide synthase (NOS) inhibitor
(1-NG-monomethyl-arginine; L-NMMA) was greater in
premenopausal women than age-matched men suggest-
ing reduced basal nitric oxide production in men com-
pared with women16.
Studies on a group of premenopausal women who un-
derwent bilateral ovariectomy were performed by mea-
suring changes in forearm blood flow induced by intra-
-brachial administration of acetylcholine before ovari-
ectomy, one month after ovariectomy and three months
after the start of estrogen replacement therapy. Com-
pared with the normal values before ovariectomy, acetyl-
choline-induced vasodilatation was significantly reduced
after ovariectomy and was restored after use of exoge-
nous 17b-estradiol17. Another such group was studied by
examining the effect of intra-brachial administration of
vitamin C (an antioxidant that scavenges super-oxide
free radicals) on changes in forearm blood flow. Before
ovariectomy there was not difference in vasodilatatory
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response to acetylcholine, whereas one month after ova-
riectomy vitamin C significantly corrected the response
to acetylcholine18. These results suggest that ovariecto-
my could be associated with an increase in oxidative
stress and that the beneficiary effects of hormonal re-
placement therapy might be a result of vascular oxida-
tive stress reduction.
The effects of estrogens/testosteron on vascular func-
tion were studied in male to female transsexuals taking
oral estrogen therapy during 5 months and compared
with age-matched men and premenopausal women. Tran-
sexuals had plasma testosterone reduced to the concen-
trations found in premenopausal women. Measurement
of flow-mediated vasodilatation showed that it was lower
in men than in estrogens-treated male to female trans-
sexuals or in premenopausal women19. Another study
showed that castrated male to female transsexuals trea-
ted with estrogen for an average of 5 years had signifi-
cantly greater endothelium-dependent vasodilatation
compared with male control subjects20. Taken together,
these studies suggest that endothelium dependent va-
sodilatation is improved in the condition with chronic
estrogens supplementation or testosterone levels reduc-
tion3.
Crucial Role of Estrogens and Progesterone
Great majority of contemporary studies highlights
the protective role of estrogens and progesterone against
the development of CVDs. Many studies have demon-
strated that estrogen stimulates endothelium-dependent
mechanism of vascular smooth muscle cell (VSMC) relax-
ation by two different pathways. In the genomic path-
way, estrogen binds to endothelial cytosolic/nuclear es-
trogen receptors, increases gene transcription, endothe-
lial cell proliferation, and increases endothelial nitric-
-oxide production21–39. In the non-genomic pathway, es-
trogen binds to membrane receptors on endothelial cell
surface and causes an increase of endothelial nitric oxide
production. Nitric oxide diffuses into the VSMC, binds to
guanylate cyclase and increases cGMP, which subse-
quently causes relaxation by decreasing calcium concen-
tration. Endothelial estrogen receptors may activate
cyclo-oxygenases and increase PGI2 production. PGI2
leads to relaxation of VSMC through the activation of po-
tassium channels2.
Estrogens have a protective role in the development
of atherosclerosis by interacting with various pathogenic
factors. They decrease levels of total plasma cholesterol
and low density lipoproteins (LDL) and increase high
density lipoproteins (HDL) and triglycerides by influenc-
ing expression of hepatic apoprotein genes. Estrogens
modify LDL receptors on hepathocytes, increasing the-
reby LDL intake and subsequently decreasing plasma
LDL level21. Due to the presence of a phenol ring struc-
ture in 17-b-estradiol, estrogen may act as an antioxidant
suppressing the uptake of LDL-cholesterol by the arte-
rial wall, or enhancing endothelial degradation of LDL-
-cholesterol22. Estrogens with a phenol structure protect
LDL from cellular and calcium ion mediated oxidation in
vitro23,24. The mechanisms of LDL oxidation in vivo are
still unknown. It has been hypothesized that vascular
cells modify LDL into its atherogenic form25,26 but reduc-
tion-oxidation active metals in the vascular wall may act
on sub-endothelial lipoproteins27. Short-term exposure
to physiological concentrations of estradiol had the po-
tential to increase LDL resistance to calcium ion medi-
ated modification28. Furthermore, estrogens interfere
with monocyte adherence to the intimae surface of endo-
thelium and with the sub-endothelial migration of mono-
cytes29.
Lower estrogen levels, lower sex hormone binding
globulin (SHGB) and higher androgen levels have been
hypothesized by Rexrode et al to predict higher risk of
CVD in postmenopausal women30. They discovered that
postmenopausal women who are not using HRT have
lower SHBG and higher free androgen index (FAI) and
that they have increased risk of CVD. Postmenopausal
women who are current HRT users have no clear associa-
tions between estrogen, androgen, or SHBG levels and
risk of CVD. Liu et al31 implied that there are three
phases of hormonal milieu changes. The first is pre-me-
nopause, occurring before estrogens levels start to de-
cline, which is approximately two years before meno-
pause, the second is inter-menopause, which occurs ap-
proximately around the age of 55 years, and the third is
post-menopause. During inter-pause, estrogens levels de-
cline rapidly around menopause, while there is a more
gradual decline of androgen levels up to age 55. The
aromatization of androgens to estrogens increases with
age and androgens may be the only source of estradiol in
post-pause. It has been discovered that early menopause
is associated with increased CVD risk. In the inter-meno-
pause hormonal milieu is relatively more androgenic
than in either pre-menopause or post-menopause. They
hypothesized that if the inter-menopause period in wo-
men lasts longer, the CVD risk will be higher.
Acute (short-term) administration of estrogens can
cause rapid vasodilatation and increased blood flow. The
rapid time-course of this estrogens-induced response ru-
les out modulation of gene expression as a potential
mechanism. Instead, the acute effects of estrogens are
likely to be mediated through the novel (non-genomic)
signal transduction pathway. The results of some investi-
gations have suggested that estrogens elicit rapid effects
by modulating VSM ion channels. For example, studies
have shown that estrogens act like a calcium channel an-
tagonists, thereby decreasing the influx of calcium into
VSM. Inhibition of calcium influx would inhibit con-
traction3.
Studies in primates and other animal models support
evidence that the beneficial effects of HRT in preventing
atherosclerosis occur only if HRT is initiated before the
development of advanced atherosclerosis (the time hy-
pothesis)21. The Heart and Estrogens/progestin Replace-
ment Study (HERS) was a randomized trial involving
nearly 3000 postmenopausal women under 80 years of
age (mean 66.7 years) who had a history of coronary ar-
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tery disease (CAD)30. The women were treated with ei-
ther placebo or combination hormone therapy (0.625 mg
of conjugated estrogens and 2.5 mg of medroxyprogeste-
rone daily). Interestingly, no significant differences in
primary outcome (CVD death or nonfatal myocardial in-
farction) or secondary outcome (stroke, peripheral arte-
rial disease, congestive heart failure, resuscitated arrest,
unstable angina) were noted between the hormone-trea-
ted groups and those treated with placebo after a 4-year
follow-up, despite a favorable effect of hormone therapy
on lipid profiles30. It was found, however, that more
women in the hormone-treated group suffered coronary
events during the first year of treatment than those tak-
ing the placebo. Women in the hormone-treated group
also experienced more thrombosis events, such as pulmo-
nary embolism. The Estrogens in the Prevention of Ath-
erosclerosis Trial was organized to assess estrogens abil-
ity to attenuate the progression of sub clinical atheroscle-
rotic plaques, and the protocol included postmenopausal
women with no history of CVD receiving unopposed
doses of b-estradiol to ensure no interference from pro-
gesterone. This trial concluded that unopposed estradiol
treatment can slow the progression of sub clinical ath-
erosclerosis to much the same extent as traditional li-
pid-lowering therapy. It assumed that estrogens bind to
alpha and betha intracellular receptors influencing NO,
cytokine and growth factors production (30), thus affect-
ing vascular endothelial function. Much research atten-
tion has been focused on the effects of estrogens and
HRT on blood coagulation and the formation of emboli,
because these are major risk factors for CVD and myo-
cardial infarction, and it has been demonstrated that lev-
els of several coagulation factors such as factors VII and
VIII as well as fibrinogen increase after menopause. It
has been shown that estrogens may exert anticoagulant
effects by interfering with platelet aggregation. After a
blood-vessel wall is injured, collagen fibres allow for
platelets to adhere to the injury site, and the platelets si-
multaneously produce several compounds involved with
coagulation32. Faraday et al.33 found that the number of
platelet GPIIb/IIIa receptors was the same between
healthy young men and women, but in premenopausal
women these receptors were more responsive to platelet-
-activating endogenous signals and platelet-activating
drugs compared with age-matched men. This finding
would tend to increase platelet aggregation in women3.
ET-1 levels were found to be significantly lower in wo-
men compared with men, and were lowest in pregnant
women3.
In early postmenopausal women, like the ones in-
cluded in the observational studies, ovarian hormone re-
placement may be cardio protective because of the re-
sponsiveness of the endothelium to estrogens that also
buffer the detrimental effects of coagulation. In late
postmenopausal women ovarian hormones have either a
null effect or even a detrimental effect on the risk of vas-
cular disease because of the predominance of the procoa-
gulant or plaque-destabilizing effects over the vasopro-
tective effects. Therefore, HRT has beneficial cardiovas-
cular effects in younger women while it may have detri-
mental effect on coagulative balance and vascular inflam-
mation and has little effect on cardiovascular functions
in older women (34). Estrogen exerts their protective ef-
fects in CVD by changes in lipoproteins; decreasing LDL-
-cholesterol, apolipoprotein B and lipoprotein(a) and in-
creasing HDL-cholesterol and apolipo- protein A1. In
post-menopause, there are also evident changes in homo-
cysteine (independent risk factor for CVD which homeo-
stasis is influenced by sex hormones) and carbohydrate
metabolism, as well as unfavorable alterations in lipid
profile, and in haemostasis, all related to atherosclerosis
and identified as a part of a metabolic syndrome22. The
protective effects of HRT may be exerted by changes of
the profile of coagulation factors to more physiological
(pre-menopausal) profile, and by affecting serum glucose
and insulin concentration, as well as by decrease in
homocysteine concentration22. Oral contraceptives, which
are suppressing ovarian production of endogenous estro-
gens, increase the risk of various CVDs, which are re-
lated to impaired endothelial function. Synthetic estro-
gens have less effective function than endogenous one on
endothelial cells35–37, but this can be disputed. John et al
have proved that there were no significant differences
between vascular vasodilatation in response to acetyl-
choline and sodium nitroprusside between healthy pre-
menopausal women taking oral contraceptives and wo-
men not taking them. In the other hand, there was a
highly significant difference in response to L-NMMA ad-
ministration with a greater vasoconstrictive response af-
ter stimulation with acetylcholine in women with oral
contraception than in those without therapy. Conclusion
was that increased basal production and release of nitric
oxide in premenopausal women receiving oral contracep-
tives had protective effect of estrogens on vascular relax-
ation mechanisms38.
Use of oral contraceptives has long been associated
with increased risk of venous thromboembolism. This
thrombotic risk was attributed only to the estrogens in
the pills. This theory was challenged after 1995 by impli-
cating the progesterone role. The first-generation oral
contraceptives of the 1960s and 1970s were associated
with both ischemic and hemorrhagic stroke, which is al-
most eliminated in young women who do not smoke us-
ing the second-generation oral contraceptives with their
lower dose of estrogens39. However, one should be aware,
that there could be increased risk of stroke in smokers
and in those with high blood pressure, even among those
women using second-generation oral contraceptives. In-
terestingly, the usage of third-generations oral contra-
ceptives is associated with significantly higher risk of ve-
nous thromboembolism compared with the usage of
levonorgestrel-containing second-generation oral contra-
ceptives, and even higher risk of venous thrombosis com-
pared with non-users. Third-generation oral contracep-
tives with their low androgenic activity increase HDL
and decrease LDL. Association between third-generation
oral contraceptives and a smaller risk of stroke compared
B. Atali} et al.: Sex Steroid Hormones and Cardiovascular Diseases Development, Coll. Antropol. 33 (2009) 2: 673–680
676
with second-generation oral contraceptives remains to be
established39.
Diverse Role of Testosterone and
Other Androgens
Contemporary studies about the role of testosterone
and other androgens in the development of CVDs could
be divided into three groups: first incentive, second di-
verse, and third protective. From literature analysis one
can see early enthusiasm for use of testosterone in car-
diac patients, subsequent disappointment with andro-
gens due to negative effects on lipid metabolism, and re-
cent renewed interest as new technologies has led to
re-examination of the adverse effects of androgens.
Studies that highlight the incentive role of testoster-
one in CVDs are overwhelmingly made in female popula-
tion. It is proven that visceral fat accumulation occurring
in postmenopausal women is connected with hypoestro-
genism, deceased production of sex-hormone binding glo-
bulin (SHBG) and with rise in free testosterone. Adipose
tissue produces adipocytokines: adiponectin, lepton and
resisting40. All three hormones are connected with insu-
lin resistance, increased pressure and hypertriglyceri-
daemia. All these conditions lead to CVDs (40). Popula-
tion based study on 513 naturally postmenopausal
women aged between 54 and 67 years has shown positive
connection between high dose estrogen –testosterone
therapy and severe atherosclerosis of the aorta, but only
after one year of therapy41. Studies have also shown that
long-term treatment with high-dose androgens is associ-
ated with impaired vascular reactivity in genetic females,
consistent with a deleterious effect of androgen excess on
arterial physiology42. This proatherogenic action of an-
drogens could be explained through an elongation of
GAG (glycoseaminoglicane) chains on proteoglycans in
an androgen receptor-dependent manner43. It is proven
that adolescent girls with polycystic ovary syndrome
(PCOS) have increased levels of factors making the Met-
abolic syndrome (MetS) than adolescent girls with regu-
lar cycles44 and that overweight women with PCOS have
increased cardiovascular risk factors and evidence of
early CVD, compared with weight-matched controls45.
There is also number of studies that shows diverse ef-
fects of androgens. They claim that hyperandrogenism,
as isolated androgen excess, has not been clearly recog-
nized as a risk factor for cardiovascular diseases46. Long-
-term studies examining the prevalence of cardiovascular
diseases among women with PCOS have not demon-
strated a clear increased risk of CVDs. Their risk factors
are mainly dependant on the metabolic components, in-
sulin resistance and adiponectin hypo-secretion46. Com-
munity based cross-sectional study on 587 non-health-
-care-seeking women has shown that endogenous testos-
terone and the adrenal pre-androgens per se are not sig-
nificantly independent determinants of circulating high
sensitivity CRP and or lipoprotein lipids47. Literature re-
search conducted at Mayo Clinic has shown that testos-
terone use in men with low testosterone levels leads to
inconsenquentional changes in blood pressure, glycae-
mia and all lipid fractions (cholesterol, triglycerides,
LDL, HDL)48. Prospective cohort community-based stu-
dy in Framingham, Massachusetts, USA has shown that
serum testosterone and DHEA-S levels were not statisti-
cally significantly associated with incident CVD49. An-
drogens have important biological roles in young women,
with good effects on bone, muscle mass, mood, well-being
and libido, but also negative effects like hirsutism and
acne, which reverse with discontinuation of treatment50.
Fair evidences exist that the use of testosterone in combi-
nation with hormone therapy has both benefits and
risks. The benefits are an improvement in sexual func-
tion, an improved sense of well-being and a reduction in
triglyceride levels. The most consistent risk is a reduc-
tion in high-density lipoprotein (HDL) cholesterol51.
Studies that prove protective role of testosterone in
CVDs are the most numerous53–73. They show that an-
drogens in general and testosterone in particular may
have some protective effects on the cardiovascular sys-
tem through their metabolic and direct effects upon hu-
man vasculature52. In study of ex vivo vascular reactivity
of fresh subcutaneous resistance arteries in men suffer-
ing from heart failure, testosterone induced an acute
concentration – dependent vasodilatation of resistance
arteries at concentrations over 1 micromole/L53. Results
of various studies suggest that testosterone can alter vas-
cular tone through in both, endothelium-dependent and
endothelium-independent mechanisms. Testosterone’s
endothelium-dependent effects are likely mediated at
least in part through nitric oxide (NO) release, whereas
mechanisms of endothelium-independent effects involve
activation of one or more types of smooth muscle ion con-
ductance channels54. Testosterone can either activate
K+ channels or block Ca2+ channels55. Because vascular
cells contain sex steroid hormone receptors, testosterone
can exert effects on the vascular wall, either by itself or
through aromatization in estrogens56. The interaction of
testosterone with its specific receptors may trigger not
only long-term genomic effects, but also acute non-ge-
nomic vasodilator responses. Testosterone may activate
the endothelium and stimulate the nitric oxide-cGMP
and the hyperpolarization-mediated vascular relaxation
pathway. It may also inhibit the signaling mechanisms of
smooth muscle contraction such as [Ca2+] and protein
kinases57.
Numerous studies have shown that in ageing men tes-
tosterone levels decline together with cognitive function,
muscle and bone mass, sexual hair growth, libido and
sexual activity, but the risk of cardiovascular risk in-
creases58. The Baltimore Longitudinal Study of Aging
suggests that influence of low testosterone levels on the
cardiovascular system in men may be mediated in part
via the effects of testosterone on vascular structure and
function59. Population based cross sectional study has
shown negative correlation between total testosterone
and sex hormone binding globulin serum levels and
intimae-media thickness (IMT) in men60. The Massachu-
setts Male Aging Study, a population based cohort of
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1709 men observed at three time points (T1=1987–1989;
T2=1995–1997; T3=2002–2004) has shown that low se-
rum sex hormone binding globulin (SHBG), low total tes-
tosterone and clinical androgen deficiency are associated
with increased risk of developing MetS (central obesity,
lipid and insulin dysregulation and hypertension), par-
ticularly in non-overweight, middle-aged men (BMI un-
der 25), that can lead to development of cardiovascular
diseases61. Hypoandrogenaemia (hypogonadism, hypo-
testosteronaemia) may be a common accompanying fac-
tor in men with the MetS (Raven’s syndrome or syn-
drome X). When they are present together they may be
considered as a specific entity, the hypo-androgen-meta-
bolic (HAM) syndrome62. Healthy men with low testos-
terone levels have increased cardiovascular risk factors,
including high fasting and 2-hour plasma glucose, serum
triglycerides, total cholesterol and low-density lipopro-
tein (LDL) cholesterol, and apo-A-I lipoprotein. Injec-
tions of testosterone decrease total cholesterol and LDL
cholesterol, while increasing high-density lipoprotein
(HDL) cholesterol. Testosterone affects the clotting sys-
tem by increasing thromboxane A2 receptor activity and
platelet aggregability. Testosterone also augments the
fibrinolytic system and antithrombin III activity, has
antianginal effects, and an inverse relationship to sys-
tolic blood pressure63. Aging in men is accompanied by a
progressive, but individually variable decline of serum
testosterone production and the clinical picture of aging
in men is reminiscent of that of hypogonadism in young
men64. Middle-aged men with symptoms of andropause,
together with absolute or compensated testosterone defi-
ciency, show increased carotid IMT65. It was proven that
low free testosterone coexists with inflammation and
they both affect the process of atherosclerosis in old-age
male66.
Although, there are numerous studies showing the
negative impact of testosterone on women regarding
CVDs development, there are also results proving its pos-
itive impact. According to them development of CVDs in
postmenopausal women is due to not only estrogen, but
also testosterone decline67. Meta analysis of 101 non-
-obese postmenopausal women through medical histo-
ries, physical examinations and biochemical analysis has
shown possible protective role of endogenous androgens
at least on carotid atherosclerosis68.
There are also results showing higher total testoster-
one and SHBG to be inversely related to carotid athero-
sclerosis, suggesting their potential importance in reduc-
ing atherosclerotic risk in postmenopausal women not
using hormonal replacement therapy (HRT)69. In post-
menopausal women endogenous steroid precursors and
androgens are inversely related to IMT, an established
marker of atherosclerosis70.
These studies have thus revealed an estrogen-andro-
gen paradox: those endogenous sex hormones may relate
both to atherosclerotic cardiovascular disease and its risk
factors oppositely in women and men71. In the case of an-
drogens, hypo-androgenemia in men and hyper-andro-
genemia in women are associated with increased risk of
coronary artery disease, but also with visceral obesity, in-
sulin resistance, low high-density lipoprotein (HDL) cho-
lesterol, elevated triglycerides, low-density lipoprotein
(LDL) cholesterol and plasminogen activator inhibitor
(PAI-1). Exogenous androgens, on the other hand, induce
both apparently beneficial and deleterious effects on car-
diovascular risk factors by decreasing serum levels of
HDL-C, plasminogen activator inhibitor (PAI-1), lipopro-
tein (a), fibrinogen, insulin, leptin and visceral fat mass
in men as well as in women72. Testosterone treatment is
reported to reduce serum levels of the proinflamatory
cytokines interleukin (IL)-1b and tumour necrosis factor
(TNF)-a, and to increase levels of the anti-inflammatory
cytokine IL-10; to reduce vascular cell adhesion molecule
(VCAM)-1 expression in aortic endothelial cells; to pro-
mote vascular smooth muscle and endothelial cell prolif-
eration; to induce vasodilatation and to improve vascular
reactivity, to reduce serum levels of the pro-thrombotic
factors PAI-1 and fibrinogen; to reduce LDL-C; to im-
prove insulin sensitivity; and to reduce body mass index
and visceral fat mass73.
Conclusion
In this review we have attempted to evaluate the role
of the sex steroid hormones in the development of the
cardiovascular diseases (CVDs). The interaction of sex
hormones on the blood vessel receptors, the vascular re-
activity and the pathogenesis of CVDs were examined.
We have highlighted not just the protective role of estro-
gens, but also the protective role of testosterone, on one
side, and the incentive role of both of them on the other
side, which is gender dependent. It is clear that sex ste-
roid hormones are important in physiological function of
vasculature, as well as in pathogenesis of vascular dis-
eases, but to fully understand all the complex interac-
tions of sex hormones with pathogenesis factors and pro-
cesses, further research is necessary. If one intends to
effectively use the known facts of sex hormone physiol-
ogy to influence cardiovascular diseases, to safely manip-
ulate the sex hormone system and thereby to improve
therapy, one has to elucidate all important mechanisms
before we can possibly modify them to our advantage at
first.
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RAZLI^ITE ULOGE SPOLNIH STEROIDNIH HORMONA U PATOGENEZI VASKULARNE
DISFUNKCIJE I RAZVOJU KARDIOVASKULARNIH BOLESTI KOD MU[KARACA I @ENA
S A @ E T A K
U ovom radu predstavljen je pregled najnovije literature, koja analizira odnose izme|u spolnih steroidnih hormona i
kardiovaskularnih bolesti. Analiziran je utjecaj spomenutih hormona na tri razine: njihovu interakciju s krvo`ilnim
receptorima, njihovu modulaciju vaskularne funkcije, te ulogu u patogenezi kardiovaskularnih bolesti. U radu su istak-
nute ne samo poznate ~injenice protektivne uloge estrogena i poticajnog utjecaja testosterona, ve} su dani pojedina~ni
primjeri njihovog suprotnog u~inka.
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